When CMEA was enacted, we foresaw the one-day emergence of new, innovative technologies that prevented easy extraction and conversion of pseudoephedrine from cold medications into meth.
We granted the Drug Enforcement Administration full authority to exempt from purchase restrictions any pseudoephedrine products that might come closer, by making conversion less economical.